Published in Medical Patent Business Week, November 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Ortec International.
Report 1: Ortec International, Inc. (OTCI) announced that a preliminary review of the un-audited data of all the patients treated in its recently completed confirmatory trial indicates OrCel healed more wounds and achieved 100% wound closure of those wounds sooner in comparison to the control group.
Statistical significance was achieved for the primary clinical endpoints of incidence of patients achieving 100% wound closure as well as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week